Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Marketable Securities: ¥376 Mil (As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

SHSE:688266 Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
69 GF Score
Price ¥121.08
GF Value ¥221.93
Valuation Significantly Undervalued
! 4 Warning Signs
View Full Analysis

What is Suzhou Zelgen Biopharmaceuticals Co Marketable Securities?

Suzhou Zelgen Biopharmaceuticals Co SHSE:688266 +1.15% 69 Marketable Securities is ¥376 Mil as of Jun. 2026. GuruFocus rates SHSE:688266 with a GF Score™ of 69/100 and a GF Value™ of ¥221.93 (Significantly Undervalued). The stock has 4 warning signs investors should review.

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price. Suzhou Zelgen Biopharmaceuticals Co's Marketable Securities for the quarter that ended in Jun. 2026 was ¥376 Mil.

Suzhou Zelgen Biopharmaceuticals Co's annual Marketable Securities declined from Dec. 2023 (¥137 Mil) to Dec. 2024 (¥41 Mil) and declined from Dec. 2024 (¥41 Mil) to Dec. 2025 (¥0 Mil).

Suzhou Zelgen Biopharmaceuticals Co  (SHSE:688266) Marketable Securities Explanation

Marketable Securities are very liquid as they tend to have maturities of less than one year. Furthermore, the rate at which these securities can be bought or sold has little effect on their prices.

Please note, GuruFocus' Marketable Securities also includes "Other Short Term Investment".

Suzhou Zelgen Biopharmaceuticals Co Marketable Securities Related Terms

Suzhou Zelgen Biopharmaceuticals Co Marketable Securities Historical Data

* Premium members only.

The historical data trend for Suzhou Zelgen Biopharmaceuticals Co's Marketable Securities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Suzhou Zelgen Biopharmaceuticals Co Marketable Securities Chart

Suzhou Zelgen Biopharmaceuticals Co Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Marketable Securities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 65.26 248.93 137.02 40.50 0.00

Suzhou Zelgen Biopharmaceuticals Co Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Marketable Securities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 33.97 16.20 0.00 465.53 375.58
SHSE:688266
69GF Score
Suzhou Zelgen Biopharmaceuticals Co Ltd SHSE:688266
Marketable Securities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Suzhou Zelgen Biopharmaceuticals Co Marketable Securities Calculation

Marketable Securities are very liquid securities that can be converted into cash quickly at a reasonable price.

Frequently Asked Questions Learn more about Marketable Securities →
What does a Marketable Securities of ¥376 Mil mean?
Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) has a Marketable Securities of ¥376 Mil as of Jun. 2026. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors.
Is Suzhou Zelgen Biopharmaceuticals Co's Marketable Securities too high?
Suzhou Zelgen Biopharmaceuticals Co's current Marketable Securities is ¥376 Mil. Overall, Suzhou Zelgen Biopharmaceuticals Co has a GF Score™ of 69/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Suzhou Zelgen Biopharmaceuticals Co's Marketable Securities compare to VRTX and REGN?
Suzhou Zelgen Biopharmaceuticals Co's Marketable Securities of ¥376 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Marketable Securities for a Biotechnology company?
A good Marketable Securities depends on the Biotechnology industry context. However, Marketable Securities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Marketable Securities mean?
A high Marketable Securities can signal that a stock is expensive relative to its fundamentals. Marketable securities are high-liquid securites not directly classified as cash or cash equivalents. View historical data on Suzhou Zelgen Biopharmaceuticals Co and its competitors. Suzhou Zelgen Biopharmaceuticals Co's current Marketable Securities is ¥376 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Suzhou Zelgen Biopharmaceuticals Co stock overvalued right now?
Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) is currently considered Significantly Undervalued. The stock's GF Value™ is ¥221.93, compared to a current price of ¥121.08 — trading 45.4% below its estimated fair value. The current Marketable Securities is ¥376 Mil. Suzhou Zelgen Biopharmaceuticals Co's overall GF Score™ is 69/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Marketable Securities calculated?
Marketable Securities is calculated from a company's financial statements. For Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266), the current Marketable Securities is ¥376 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Suzhou Zelgen Biopharmaceuticals Co (SHSE:688266) Overvalued in 2026?

Based on GuruFocus' analysis, Suzhou Zelgen Biopharmaceuticals Co stock appears to be undervalued. The current stock price of ¥121.08 is trading 45.4% below its estimated GF Value™ of ¥221.93. GuruFocus considers Suzhou Zelgen Biopharmaceuticals Co to be Significantly Undervalued.

Key valuation signals for SHSE:688266:

  • Marketable Securities: ¥376 Mil
  • GF Value™: ¥221.93 vs. price of ¥121.08 (45.4% below fair value)
  • GF Score™: 69/100 with 4 warning signs

No single metric tells the full story. See the SHSE:688266 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Suzhou Zelgen Biopharmaceuticals Co Business Description

Address No.209 Chenfeng Road, Yushan Town, Jiangsu Province, Kunshan, CHN
Suzhou Zelgen Biopharmaceuticals Co Ltd is engaged in research and development of new chemical and biological drugs for various therapeutic areas, including tumors, bleeding and blood diseases, and hepatobiliary diseases.
69GF Score

Get the complete analysis for SHSE:688266

Marketable Securities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

¥121.08
Price
¥221.93
GF Value